SequelSEC

SkinHealth Systems Inc. SKIN

Surgical & Medical Instruments & Apparatus · CIK 0001818093 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$300.79M
Fiscal year ended 2025-12-31
Operating income
-$20.80M
Fiscal year ended 2025-12-31
Free cash flow
$37.18M
Fiscal year ended 2025-12-31

SkinHealth Systems Inc. (SKIN) reported revenue of $300.79M and net income of -$9.52M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from SkinHealth Systems Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

SkinHealth Systems Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$300.79M$334.29M$397.99M$365.88M$260.09M$119.09M$166.62M
Cost of revenue$104.43M$152.00M$242.88M$117.10M$81.55M$51.89M$60.11M
Gross profit$196.36M$182.30M$155.11M$248.78M$178.54M$67.20M$106.51M
Operating income-$20.80M-$67.77M-$130.92M-$25.84M-$39.93M-$17.18M$13.46M
Net income-$9.52M-$29.10M-$100.12M$44.22M-$378.76M-$29.18M-$1.64M
Research & development$5.63M$6.30M$10.10M$8.44M$8.20M$3.41M$4.61M
Weighted-average diluted sharesshares 135.80Mshares 142.49Mshares 131.68Mshares 148.51Mshares 102.11Mshares 34.29Mshares 32.14M
Pretax income-$5.94M-$29.55M-$101.89M$45.34M-$380.64M-$38.48M-$2.94M
Income tax expense$3.58M-$452.00K-$1.77M$1.12M-$1.88M-$9.31M-$1.30M
Diluted EPS$-0.16$-0.36$-0.76$-0.23$-3.71$-0.85$-0.05
Selling, general & administrative$211.54M$243.77M$275.93M$266.18M$210.27M$80.97M$88.44M
General & administrative$117.95M$125.46M$131.43M$106.10M$98.69M$30.65M$26.66M
Selling & marketing$93.59M$118.31M$144.50M$160.08M$111.58M$50.32M$61.77M

Balance

SkinHealth Systems Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalentsUnavailableUnavailable$523.02M$568.20M$901.89M$9.49MUnavailable
Total assets$499.80M$685.68M$929.11M$1.00B$1.22B$222.84MUnavailable
Current assets$309.52M$477.12M$698.25M$783.28M$1.00B$59.10MUnavailable
Total liabilities$438.75M$633.88M$869.72M$836.03M$916.51M$252.80MUnavailable
Current liabilities$186.28M$68.15M$115.01M$71.71M$76.44M$30.93MUnavailable
Total equity incl. NCI$61.06M$51.80M$59.39M$167.05M$298.03M-$30.57M-$1.21M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable$460.00MUnavailable
Inventory$48.01M$69.11M$91.32M$109.66M$35.26M$23.20MUnavailable
Accounts receivable$21.74M$27.64M$54.70M$76.49M$46.82M$18.58MUnavailable
Goodwill$126.62M$123.50M$125.82M$124.59M$123.69M$98.53M$98.52M
Long-term debtUnavailable$552.20MUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$15.63M$21.94M$44.77M$28.47M$29.05M$18.48MUnavailable

Cash flow

SkinHealth Systems Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow$37.48M$16.13M$21.75M-$106.60M-$28.36M-$12.44M$1.73M
Capital expenditures$303.00K$756.00K$3.82M$10.85M$11.20M$3.50M$8.77M
Investing cash flow-$5.16M-$6.79M-$31.51M-$18.87M-$37.73M-$3.82M-$12.48M
Financing cash flow-$174.93M-$158.34M-$37.45M-$205.24M$959.04M$18.27M$14.58M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$14.82M$26.70M$22.54M$28.50M$12.42M$363.00K$103.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$0$0$30.16M$160.00M$0$154.00K$0
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

SkinHealth Systems Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow$37.18M$15.38M$17.92M-$117.45M-$39.56M-$15.94M-$7.05M
Gross margin65.3%54.5%39.0%68.0%68.6%56.4%63.9%
Operating margin-6.9%-20.3%-32.9%-7.1%-15.4%-14.4%8.1%
FCF margin12.4%4.6%4.5%-32.1%-15.2%-13.4%-4.2%
SBC / revenue4.9%8.0%5.7%7.8%4.8%0.3%0.1%
Current ratio1.66x7.00x6.07x10.92x13.09x1.91xUnavailable
Revenue YoY growth-10.0%-16.0%8.8%40.7%118.4%-28.5%Unavailable
Net margin-3.2%-8.7%-25.2%12.1%-145.6%-24.5%-1.0%
R&D / revenue1.9%1.9%2.5%2.3%3.2%2.9%2.8%
CapEx / revenue0.1%0.2%1.0%3.0%4.3%2.9%5.3%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable2.5%UnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SKIN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2021-12-31

Difference 4263000 exceeds tolerance 1218806.000. Presentation or filing-vintage differences need review.

balance equationreview2020-12-31

Difference 459394441 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.